Brexucabtagene autoleucel (Intravenous)
Medically reviewed by Drugs.com. Last updated on Mar 6, 2022.
Warning: Cytokine Release Syndrome and Neurologic ToxicitiesCytokine Release Syndrome (CRS), including life-threatening reactions, occurred in patients receiving brexucabtagene autoleucel. Do not administer brexucabtagene autoleucel to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.Neurologic toxicities, including life-threatening reactions, occurred in patients receiving brexucabtagene autoleucel, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with brexucabtagene autoleucel. Provide supportive care and/or corticosteroids, as needed.Brexucabtagene autoleucel is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Yescarta(TM) and Tectartus(TM) REMS Program .
Commonly used brand name(s)
In the U.S.
- Tecartus
Available Dosage Forms:
- Suspension
Therapeutic Class: Immunological Agent
Chemical Class: CAR T-Cell Agent
Uses for brexucabtagene autoleucel
Brexucabtagene autoleucel injection is used to treat mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL) in patients who have received other cancer medicines but did not work well.
Brexucabtagene autoleucel is an antineoplastic (cancer) medicine that is made from your own white blood cells, which have been modified to recognize and attack your cancer cells. Before you begin treatment, talk to your doctor about the benefits of brexucabtagene autoleucel as well as the possible risks of receiving it.
Brexucabtagene autoleucel is available only under a restricted distribution program called the Yescarta™ and Tecartus™ REMS (Risk Evaluation and Mitigation Strategy) Program.
Before using brexucabtagene autoleucel
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For brexucabtagene autoleucel, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to brexucabtagene autoleucel or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of brexucabtagene autoleucel injection in the pediatric population. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of brexucagtagene autoleucel injection in the elderly.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Interactions with medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be use..
